Previous 10 | Next 10 |
Call to be held on Monday, November 22 nd at 10:00am ET BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the devel...
Timber Pharmaceuticals (NYSE:TMBR): Q3 GAAP EPS of -$0.08. Revenue of $266,974 (-20.6% Y/Y) Press Release For further details see: Timber Pharmaceuticals reports Q3 results
Positive Top Line Phase 2b Study Data for Lead Asset TMB-001 and Capital Rais e of $17.25 Million Announced Subsequent to Quarter End BASKING RIDGE, NJ, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber"...
Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ - ( NewMediaWire ) - November 09, 2021 - Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the...
Underwritten Public Offering Resulted in Total Gross Proceeds of $17.25 Million Basking Ridge, NJ, Nov. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a b...
Basking Ridge, NJ, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare an...
Basking Ridge, NJ - ( NewMediaWire ) - November 03, 2021 - Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic di...
Timber Pharmaceuticals (NYSE:TMBR) trades 21.3% down after hours on announcing its offer to sell shares in an underwritten public offering; each share will be sold with a warrant to purchase one share. Underwriters expected to grant 30-day option to purchase additional shares. ...
Basking Ridge, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare an...
Data demonstrate reduction in targeted and overall severity of CI in patients treated with topical IPEG™ TMB-001 (topical isotretinoin) Company planning for end-of-Phase 2 meeting with FDA in the beginning of 2022 Phase 3 study is expected to begin in Q2 202...
News, Short Squeeze, Breakout and More Instantly...
Timber Pharmaceuticals Inc. Company Name:
TMBR Stock Symbol:
NYSE Market:
Timber Pharmaceuticals Inc. Website:
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that...
WARREN, NJ - ( NewMediaWire ) - November 28, 2023 - Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-...
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated d...